Development and application of a scintillation proximity assay (SPA) for identification of selectiive inhibitors of 11β-hydroxysteroid dehydrogenase type 1

Assay and Drug Development Technologies

Volumn 3, Issue 4, 2005, Pages 367-375

  Mundt, Steven ^a   Solly, K ^a   Thieringer, R ^a   Hermanowski Vosatka, Anne ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; DIMETHYL SULFOXIDE; ENZYME INHIBITOR; GLUCOCORTICOID; HYDROCORTISONE; MONOCLONAL ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRITIUM;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HORMONE METABOLISM; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; METABOLIC SYNDROME X; MICROSOME; REPRODUCIBILITY; SCINTILLATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CHO CELLS; CRICETINAE; CRICETULUS; DIMETHYL SULFOXIDE; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; METABOLIC SYNDROME X; MICROSOMES; NADP; SCINTILLATION COUNTING; TRANSFECTION; TRITIUM;

EID: 27144431970     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2005.3.367     Document Type: Article

References (17)

1. Seckl JR, Walker BR: 11Beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371-1376.
2. Albiston AL, Obeysekere VR, Smith RE. Krozowski ZS: Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type2 enzyme. Mol Cell Endocrinol 1994;105:R11-R17.
3. Bujalska IJ, Kumar S, Stewart PM: does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 26;349:1210-1213.
4. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;249:2166-2170.
5. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS: Transgenic amplication of glucocortoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112:83-90.
6. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Secklf JR, Mullins JJ: 11 Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attentuated glucocortoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997;94:14924-14929.
7. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR: Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;41293-41300.
8. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstorm G, Larsson C, Forsgen M, Ashkzari M, Nilsson CE, Fieldler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strain. Endocrinology 2003;144:4755-4762.
9. Andrews RC, Rooyackers O, Walker BR: Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinal Metab 2003;88:285-291.
10. Rask E, Olsson T, Sodeberg S, Andrew R, Livingstone DE, Johnson E, Walker BR: Tissue-specific dysregultion of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:1418-1421.
11. Rask E, Walker BR, Sodeberg S, Livingstone DE, Eliason E, Johnson O, Andrew R, Ollson T: Tissue-specific changes in peripheral cortisol metabolism in obese women: Increase adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2001;87:3330-3336.
12. Stewart PM, Corrie JE, Shackleton CH, Edwards CR: Syndrome of apparent mineralocortoid excess. A defect in the cortisol-cortisome shuttle. J Clin Invest 1988;82:340-349.
13. Schweizer RAS, Atanasov AG, Frey BM, Odermatt A: A rapid screening assay for inhibitors of 11β-hydroxysteroid dehydrogenases (11 β-HSD): Flavanone selectivity inhibits 11β-HSD1 reductase activity. Mol Cell Endocrinol 2003;212:41-49.
14. Olson S, Aster SD, Brown K, Carbin L, Graham DW, Hermanowski-Vosatka A, LeGrand CB, Mundt S, Robbins MA, Schaeffer JM, Slossberg LH, Szymonifka MJ, Thieringer R, Wright SD, Balkovec JM: Adamatyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett 2005 (in press).
15. Swinkles LM, Ross HA, Benraad TJ: Scintillation proximity assay: Determination of steroid hormones without separation of antibody-bound and free ligand. Ann Clin Biochem 1991;28(Pt 1):87-90.
16. Al-Dujaili EA, Williams BC, Edwards CR: The development and application of direct radioimmunoassay for corticosterone. Steroids 1981;37:157-176.
17. Solly K, Mundt SS, Zokian HJ, Ding GJF, Hermanowski-Vosatka A, Strulovici B, Zheng W: High throughput screening of 11β-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format. Assay Drug Dev Technol 2005;3:377-384.